APCS and idiopathic pulmonary fibrosis: A Phase 2 study trial of PRM-151, a novel anti-fibrotic immunomodulator, was reported in patients with Idiopathic Pulmonary Fibrosis (IPF)35 and in a 28-week Phase 2 trial, infusions of SAP improved lung function36,37 by inhibiting alternative activation of macrophages and fibrocyte differentiation31,32.